| abstract |
LY6K is identified herein as a promising biomarker useful for the diagnosis of cancers such as lung cancer and esophageal cancer. Similarly, it is useful for predicting the prognosis of patients with these diseases. As described in detail herein, LY6K is specifically overexpressed in most lung and esophageal cancer tissues tested and is elevated in the serum of most patients with these tumors. ing. Therefore, LY6K may be used in combination with other tumor markers to significantly improve the sensitivity of cancer diagnosis. LY6K may be used in the treatment of ESCC cells, as shown by the fact that small interfering RNA (siRNA) against LY6K inhibits cancer cell growth. In addition, LY6K molecules are also potential candidates for the development of new therapeutic methods such as antibody therapy. |